Teva, the world’s largest generic drug manufacturer, said president and CEO William S. Marth has resigned and will be replaced by Allan Oberman, who was previously SVP for North American generics. Oberman will oversee Teva’s generics business in the Americas. Marth will stay on as senior adviser to global president and CEO Jeremy Levin until his retirement at the end of next year. Teva also brought on Jill DeSimone as SVP, general manager for Teva’s global women’s health franchise.